IP Library › Granted Patent US 12,409,240
Granted Patent B2
US 12,409,240 · App. 17/697,485 · Granted Sep 9, 2025

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

Inventors: Andreas Kjaer (Frederiksberg, DK); Morten Persson (Copenhagen, DK); Jacob Madsen (Copenhagen, DK)
Assignee: CURASIGHT A/S
A61K51/088A61K38/08A61K51/08A61K51/083
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,240
App. No.
17/697,485
Granted
Sep 9, 2025
Kind
B2
Abstract

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

Claims (37)

1. A method of generating images of uPAR expression in a human by diagnostic imaging of uPAR expressing tumors involving administering an imaging agent to said human, and generating an image of at least a part of said body to which said imaging agent is administered;

wherein the imaging agent is a positron-emitting radionuclide labelled peptide conjugate, said conjugate comprising a uPAR binding peptide coupled via the chelating agent DOTA or NOTA to a 64 Cu or 68 Ga radionuclide;

wherein the peptide is selected from the group consisting of:

(D-Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu)-(Trp)-(Ser),

(Ser)-(Leu)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(Gln)-(Tyr)(Leu)-(Trp)-(Ser),

(D-Glu)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Tyr)-(Tyr)-(Leu)-(Trp)-(Ser),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu)-(Trp)-(Ser),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(Ser)-(D-Arg)-(Tyr)-Leu)-(Trp)-(Ser),

(D-Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(Ser)-(D-Arg)-(Tyr)-Leu)-(Trp)-(Ser),

(D-Thr)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu)-(Trp)-(Ser),

(D-Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu)-([beta]-2-naphthyl-L-alanine)-(Ser),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(Arg)-(Tyr)-(Leu)-(Trp)-(Ser),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu) ([beta]-1-naphthyl-L-alanine)-(Ser),

(D-Glu)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(Tyr)-(Tyr)-(Leu)-(Trp)-(Ser),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Leu)-(Leu)-(Trp)-(D-His),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-([beta]-cyclohexyl-L-alanine)-(Leu)-(Trp)-(Ile),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu) ([beta]-1-naphthyl-L-alanine)-(D-His),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(N-(2,3-dimethoxybenzyl)glycine)-(D-Phe)-(N-(3-indolylethyl)glycine)-(N-(2-methoxyethyl)glycine),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(N-(2,3-dimethoxybenzyl)glycine)-(D-Phe)-(N-benzylglycine)-(N-(2[beta]thoxyethyl)glycine),

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(N-(2,3-dimethoxybenzyl)glycine)-(D-Phe)-(N-(methylnaphthalyl)glycine)-(N-(2-methoxyethyl)glycine), and

(Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(N-(2,3-dimethoxybenzyl)glycine)-(D-Phe)-(N-(2,3-dimethoxybenzyl)glycine)-(Ile),

wherein the C-terminal is either a carboxylic acid or an amide;

wherein the conjugate is to be administered in a dose of 100-500 MBq.

2. The method according to claim 1 , wherein the peptide is (D-Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(Leu)-(Trp)-(Ser).

3. The method according to claim 1 , wherein the chelating agent is DOTA and the radionuclide is 64 Cu radionuclide.

4. The method according to claim 1 , wherein the chelating agent is DOTA and the radionuclide is 68 Ga radionuclide.

5. The method according to claim 1 , wherein the chelating agent is NOTA and the radionuclide is 64 Cu radionuclide.

6. The method according to claim 1 , wherein the chelating agent is NOTA and the radionuclide is 68 Ga radionuclide.

7. The method according to claim 1 , wherein the imaging agent has the formula:

8. The method according to claim 1 , wherein the imaging agent has the formula:

9. The method according to claim 1 , wherein the cancer is selected from prostate, breast, pancreatic, lung, brain and colorectal cancer.

10. The method according to claim 1 , wherein the conjugate is administered in a diagnostically effective amount.

11. The method according to claim 1 , wherein the conjugate is administered in a dose of 200-400 MBq.

12. The method according to claim 1 , wherein the conjugate is to be administered in a dose of 100-500 MBq followed by PET scanning ½-24 h after the conjugate has been administered, and quantification through SUVmax and/or SUVmean.

13. The method according to claim 1 , wherein the imaging agent is provided in a pharmaceutical composition comprising the imaging agent, together with one or more pharmaceutical acceptable adjuvants, excipients or diluents.

14. The method according to claim 1 , wherein the imaging agent has the formula:

15. The method according to claim 1 , wherein the imaging agent has the formula:

Assignments (2)
CHANGE OF NAME Recorded Mar 21, 2022
From: CURASIGHT APS
To: CURASIGHT A/S
Reel/Frame 059452/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2022
From: KJAER, ANDREAS; PERSSON, MORTEN; MADSEN, JACOB
To: CURASIGHT APS
Reel/Frame 059297/0577 →
Priority Claims (1)
DK PA 2012 70751 · Dec 3, 2012 · national
Continuity (5)
Division 16870776 · May 8, 2020
Division 15832371 · Dec 5, 2017
Division 14649113
Provisional Application 61732443 · Dec 3, 2012
Related Publication 20220202966A1 · Jun 30, 2022
References Cited (62)
US 6277818B1 · Mazar et al. · 2001 [cited by applicant]
US 6514710B1 · Jones et al. · 2003 [cited by applicant]
US 6896870B1 · Mazar et al. · 2005 [cited by applicant]
US 7026282B1 · Ploug et al. · 2006 [cited by applicant]
US 8568689B1 · Cuthbertson et al. · 2013 [cited by applicant]
US 9884131B2 · Kjaer · 2018 [cited by examiner]
US 10111969B2 · Kjaer et al. · 2018 [cited by applicant]
US 10159759B2 · Kjaer et al. · 2018 [cited by applicant]
US 10383961B2 · Kjaer et al. · 2019 [cited by applicant]
US 10994032B2 · Kjaer · 2021 [cited by examiner]
US 11311637B2 · Kjaer · 2022 [cited by examiner]
US 20100233082A1 · Langstrom et al. · 2010 [cited by applicant]
CN 102600489A · 2012 [cited by applicant]
WO 0125410A2 · 2001 [cited by applicant]
WO 2006036071A2 · 2006 [cited by applicant]
Li et al, Clinical Cancer Research, vol. 14, No. 15, pp. 4758-4766 (Year: 2008). [cited by examiner]
Shore et al, J. Nucl. Med., Vo. 27, No. 2, pp. 287-298 (Year: 1986). [cited by applicant]
International Search Report dated Mar. 7, 2014 for International Patent Application No. PCT/DK2013/050402, filed Nov. 29, 2013. [cited by applicant]
Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci. 2008;13:6752-6762. [cited by applicant]
Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. Elevation of urokinasetype plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J … [cited by applicant]
Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with pros… [cited by applicant]
Piironen T, Haese A, Huland H, et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem. May 2006;52(5):838-844. [cited by applicant]
Steuber T, Vickers A, Haese A, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. Apr. 1, 2… [cited by applicant]
Gupta A, Lotan Y, Ashfaq R, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. May 2009;55(5):1124-1133. [cited by applicant]
Kjellman A, Akre 0, Gustafsson 0, et al. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med. Mar. 2011 ;269(3):299-305. [cited by applicant]
Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU Int. Jan. 2010;105(2):166-169. [cited by applicant]
Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. Jun. 2011 ;50 Suppl 1 :61-75. [cited by applicant]
Shariat SF, Roehrborn CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Cl… [cited by applicant]
Rabbani SA, Ateeq B, Arakelian A, et al. An anti-urokinase plasminogen activator receptor antibody (A TN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo… [cited by applicant]
Pulukuri SM, Gondi CS, Lakka SS, et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigen… [cited by applicant]
Margheri F, D'Alessio S, Serrati S, et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther. Apr. 2005;12(8):702-… [cited by applicant]
Kriegbaum MC, Persson M, Haldager L, et al. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets. Nov. 2011; 12(12): 1711-1728. [cited by applicant]
McBride WJ, Sharkey RM, Karacay H, et al. A novel method of 18F radiolabeling for Pet. J Nuc/ Med. Jun. 2009;50(6):991-998. [cited by applicant]
Averman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with (18)F-fluorine. J Nuc/Med. Mar. 2010;51 (3):454-461. [cited by applicant]
McBride WJ, D'Souza CA, Sharkey RM, et al. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. Jul. 21, 2010;21(7):1331-1340. [cited by applicant]
D'Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg OM. Highyielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. Sep. 21, 2011 ;22(9):1793-1803. [cited by applicant]
Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of (1)(8)F-AIF-NOTA-RGD(2) for tumor angiogenesis PET imaging. Eur J Nuc/ Med Mo/Imaging. Sep. 2011;38(9):1732-1741. [cited by applicant]
Gao H, Lang L, Guo N, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AIF-NOTAPRGD2. EurJ Nuc/ Med Mo/ Imaging. Apr. 2012;39(4):683-692. [cited by applicant]
Dijkgraaf I, Franssen GM, McBride WJ, et al. PET of tumors expressing gastrinreleasing peptide receptor with an 18F-labeled bombesin analog. J Nuc/ aMed. Jun. 2012;53(6):947-952. [cited by applicant]
Heskamp S, Laverman P, Rosik D, et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nuc/ Med. Jan. 2012;53(1):1… [cited by applicant]
Hoigebazar L, Jeong JM, Lee JY, et al. Syntheses of 2-nitroimidazole derivatives conjugated with 1,4, 7-triazacyclononane-N, N′-diacetic acid labeled with F-18 using an aluminum complex method for hypoxia imaging. J Med… [cited by applicant]
Laverman P, D'Souza CA, Eek A, et al. Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol. Apr. 2012;33(2):427-434. [cited by applicant]
Ploug M, Ostergaard S, Gardsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer ce… [cited by applicant]
Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des. 2003; 9( 19): 1499-1528. [cited by applicant]
McBride WJ, D'Souza CA, Sharkey RM, Goldenberg OM. The radiolabeling of proteins by the [18F]AIF method. Appl Radiat !sot. Jan. 2012;70(1):200-204. [cited by applicant]
Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using (177)Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nuc/… [cited by applicant]
Kurdziel KA, Shih JH, Apolo AB, et al. The Kinetics and Reproducibility of 18FSodium Fluoride for Oncology Using Current PET Camera Technology. J Nuc/ Med. Aug. 2012;53(8): 1175-1184. [cited by applicant]
Persson, M. et al.: “68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers”, Nuclear Medicine and Biology, vol. 39, May 2012 (May 2012), pp. 560-5… [cited by applicant]
Persson, M. et al.: “Quantitative PET of Human Urokinase Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion”, The Journal of Nuclear Medicine, vol. 53, No. 1, Jan. 201… [cited by applicant]
Z.-B. Li et al: “Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET”, Clinical Cancer Research, vol. 14, No. 15, Aug. 1, 2008 (Aug. 1, 2008 ), … [cited by applicant]
Heribert Hanscheid et al: “PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma”, European Journal of Nuclear Medicine andMolecular Imaging, Springer, Berlin, DE, vol. 39, No. 8, Apr. 20… [cited by applicant]
Traub-Weidinger T et al: “Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.”, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, No. 1, Feb. 2010 (Feb. 2010), pp. 52… [cited by applicant]
Erik S Mittra et al: “Pilot Pharmacokinetic and Dosimetric Studies of 18 F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging a v b 3 Integrin Levels 1”, Radiology, Jul. 1, 2011 (Jul. 1, 2011), pp. 182-191, XP05528816… [cited by applicant]
European Search Report and Written Opinion for corresponding European Patent Application No. 13 860 317.0, mailed Jul. 13, 2016. [cited by applicant]
Fournier, P. et al.: “Comparative study of 64Cu/NOTA-[D-Tyr6,ßAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging”, EJNMMI research, 2012, vol. 2, p. 8. [cited by applicant]
Liu, Z. et al.: “18F, 64Cu, and 68Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of breast Cancer”, Bioconjugate Chemistry, 2009, vol. 20, No. 5, pp. 1016-1025. [cited by applicant]
Liu, Z. et al.: “Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer”, Journal of Nuclear Medicine, 2009, vol. 50, No. 7, pp. 1168-1177. [cited by applicant]
Denholt, C.L. et a.: “Evaluation of 4-[18F]f!uorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer”, Nuclear Medicine and Biology, 20… [cited by applicant]
Skovgaard et al., “Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging,” The Journal of Nuclear Medicine, vol. 58, No. 3, (2017). [cited by applicant]
Persson et al. “First-in-Human UPAR PET: Imaging of Cancer Aggressiveness, ” Theranostics, 2015, 5(12):1303-1316. [cited by applicant]
Li et al., Clin. Cancer Res., vol. 14, No. 15, pp. 4758-4766 (Year: 2008). [cited by applicant]
Reagan-Shaw et al., The FASEB Journal, vol. 22, pp. 659-661 (Year: 2007). [cited by applicant]